eoadjuvant chemoradioation for resectable, non-metastasized ductal adenocarcinoma of the pancreas - NEOPA

niversitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 410 人开始时间: 2014年1月3日最近更新: 2024年8月19日

适应症

试验速览

阶段: 3 期
状态: 尚未招募
发起方
入组人数: 410

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized controlled study
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 one（—）
性别: All

入选标准

•Histology-proven adenocarcinoma of the pancreatic head/uncinate process with a tumor size greater 2 cm (=cT2) and/or close contact to the superior mesenteric vessels (=3 mm in preoperative staging).
•No evidence of metastasis to distant organs (liver, peritoneum, lung, others).
•For determination of resectability, a multi-detector CT (MDCT) with at least 16 rows applying both oral and intravenous contrast media is performed. MDCT-based imaging focuses on the upper abdomen with native, arterial, and parenchyma phase, where the parenchyma phase should include the pelvis. Imaging criteria derived from the recent consensus definition of the Society of Surgical Oncology, the American Society of Clinical Oncology and the American Hepato-Pancreatico-Biliary Association are applied for preoperative assessment of local resectability.
•Potential Resectability: visualizable fat plane around celiac and superior mesenteric arteries, and patent superior mesenteric/portal vein (SMV/PV).
•Borderline Resectability: substantial superior mesenteric/portal vein impingement, tumor abutment on the SMA < 180°, GDA encasement up to the origin of the hepatic artery, or colonic/mesenteric root invasion.
•Karnofsky performance status = 80%
•Serum creatinine level = 3.0 mg/dl
•Serum total bilirubin level = 3.0 mg/dl in the absence of biliary obstruction (In the event of biliary obstruction, patients allocated to the CRT group must undergo interventional endoscopy or percutaneous drainage for biliary decompression. Post-interventionally, bilirubin levels should be = 3.0 mg/dl before patients are subjected to CRT. In control patients undergoing upfront surgery, serum total bilirubin levels = 10.0 mg/dl are tolerated, unless clinical and laboratory signs of severe cholangitis take place. Patients with serum total bilirubin level > 10.0 mg/dl undergo preoperative biliary decompression, preferentially by interventional endoscopy)
•White blood cell count > 3.5 x 109/ml, platelet count > 100 x 109/ml
•Ability to understand and willingness to consent to formal requirements for study participation
•Written informed consent

排除标准

•Age < 18 years
•Neuroendocrine, acinar cancer
•Cancers of the pancreatic body or tail, i.e. lesions left to the SMV
•Recurrent disease
•Infiltration of extrapancreatic organs (except duodenum and transverse colon)
•Persistent cholestasis/cholangitis despite adequate biliary stenting
•Distant metasasis
•High-grade therapyresistant stenotic gastric outlet obstruction, especially in the event of endoscopically evidenced tumor invasion into the gastroduodenal mucosa.
•Tumor specific pre-treatment
•History of gastrointestinal perforation, e.g. perforated colonic diverticulitis, abdominal abscess or intestinal fistula within 6 months prior to potential study participation
•Radiographic evidence of severe portal hypertension/cavernomatous transformation that may, at the discretion of the participating investigators, hamper surgery
•Other concurrent malignancies except for basal cell cancer of the skin and in-situ cervical cancer
•Premalignant hematologic disorders, e.g. myelodysplastic syndrome
•Severe organ dysfunctions (e.g. Liver cirrhosis = Child B; Cardio-pulmonal diseases (NYHA =III, arrhythmia Lown III/IV, global respiratory insufficiency); Ascites; Acute pancreatitis; bleeding diathesis, coagulopathy, need for full-dose anticoagulation or INR > 1.5; other severe diseases that might prevent completion of the treatment regimen)
•Chronic infectious diseases, especially immune deficiency syndromes, e.g. HIV infection, active tuberculosis within 12 months prior to potential study participation
•Severe neurologic disorders, e.g. cerebrovascular ischemia
•History of prior deep venous thrombosis or pulmonary embolism
•Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months following the trial
•Serious medical, psychological, familial, sociological or geographical conditions or circumstances potentially hampering compliance with the study protocol and follow-up
•Participation in other clinical trials during the last 6 months before allocation to trial

研究者

发起方

niversitätsklinikum Hamburg-Eppendorf

相似试验

已完成

不适用

eoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinomas or squamous cell carcinomas of the esophagusEsophageal cancerCancer

ISRCTN80832026Erasmus Medical Center, Department of Medical Oncology (Netherlands)350

已完成

2 期

Adjuvant chemotherapy for completely rsected non-small cell lung cancer with TS-1 - evaluation of predictive factors for prognosiscompletely resected non-small cell lung cancer

JPRN-UMIN000001049Division of General Thoracic Surgery, Keio University, School of Medicine,200

招募中

2 期

eoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary EfficacyOesophageal cancergastro-oesophageal junction cancerCancer - Oesophageal (gullet)

ACTRN12619000288123Southern Adelaide Local Health Network Inc52

招募中

不适用

eoadjuvant chemoradiotherapy for clinical stageIV pancreatic cancer.pancreatic cancer

JPRN-UMIN000006782Yokohama City University Gastroenterological Surgery30

已完成

2 期

eoadjuvant chemotherapy and radiotherapy for operable breast cancerbreast cancer

JPRN-UMIN000004460Osaka Medical Center for Cancer and Cardiovascular Diseases35